Navigation Links
Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals
Date:3/24/2008

Five Year Contract with Canadian Division of Global Pharmaceutical Company

Endorses Value of Millennium's Targeted Nutritional Supplement

BASKING RIDGE, N.J., March 24 /PRNewswire/ Millennium Biotechnologies, Inc. a wholly owned subsidiary of Millennium Biotechnologies Group, Inc. (OTCBB: MBTG) announced today that it has entered into a five-year exclusive distribution agreement for Resurgex(R), its nutritional formula for immuno- comprised patients, with Ferring Inc. of Canada, a division of Ferring S.A.

Under the distribution agreement Ferring will have the exclusive right to use the Resurgex trademarks and sell the Resurgex line of products in Canada. Ferring will be responsible for the marketing, distribution and sales efforts throughout Canada putting Resurgex(R) into the premium Enteral Nutritional Market. Ferring will purchase all products from Millennium Biotechnologies and will promote Resurgex to various specialist groups throughout Canada.

Richard Jeysman, President of Ferring Canada stated "Resurgex's proven success in the U.S. unequivocally demonstrates this product's ability to help immuno-compromised patients better deal with various disorders such as cancer, and afflictions of the gastrointestinal tract."

"Given the exhaustive evaluation, which they have conducted, and the size of their investment, this is a significant step for Millennium Biotechnologies in the international commercialization of our product line" stated Mark C. Mirken, President and Chief Operating Officer of Millennium Biotechnology.

Ferring S.A. is a Swiss-based, research driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of endocrinology, gastroenterology, gynecology, fertility and urology.

About Millennium:

Millennium's six marketed products form the Company's advanced line of nutritional formulas. Resurgex Select(R) is a w
'/>"/>

SOURCE Millennium Biotechnologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Millennium Over-Delivers on 2007 Goals and Financial Guidance
2. Millennium Biotechnologies Group Reports 40% Sales Increase for Resurgex Product Line in Greek Market
3. Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results
4. Millennium to Receive $40 Million Milestone Payment for Achievement of Sales Threshold for Velcade(R) (Bortezomib) for Injection
5. Millennium Ships and Records the First $200,000 of Revenue Generated From the Five-Year $20,000,000 Exclusive Purchase Order
6. Millennium Biotechnologies, Inc. Launches SURGEX(TM) the First Scientifically Validated Sports Nutritional Product Created from the Medical Markets
7. Millennium Research Group Offers New Marketrack Service that Tracks European Dental Implant Market
8. Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales
9. Millennium to Webcast Third-Quarter 2007 Financial and Operational Results
10. Life Sciences Leader Joins Millennium Board of Directors
11. Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference to Webcast Millennium Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... stimulate microbial activities in soil. These microorganisms generate plant ... in the soil or in the rhizosphere. The demand ... reducing environmental pollution and on reducing the usage of ... bio fertilizers market with analysis and forecasting of the ...
(Date:1/22/2015)... RBJ today announces the firm brokered a long-term lease totaling ... biopharmaceutical company, at Two Ledgemont Center in Lexington, ... president, and Brian Cohen , senior vice president, represented ... 95 Hayden Ave. Photo - http://photos.prnewswire.com/prnh/20150122/170765 ...
(Date:1/22/2015)... Protocol Networks brings independent technology consulting to the ... consultants, Protocol Networks has recently announced its expansion into ... his company has attracted several clients in The Constitution ... as others. With the success of these engagements, Rogers ...
(Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a project managed ... legal requirements around using controlled substances in pharmaceutical research, ... their international operations expand and become increasingly complex, large ... a result of the first phase of the CSCS ...
Breaking Biology Technology:Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 2Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 3Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 4Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Protocol Networks Brings Independent Technology Consulting to the Constitution State 2Global Compliance Service for Controlled Substances to Expand to China 2
... July 11, 2011 Generex Biotechnology Corporation ( ... of studies conducted at the Mayo Clinic using ... Inc., the Company,s wholly-owned subsidiary, has used this ... vaccines for cancer.  AE37, an Ii-Key HER-2 hybrid, ...
... July 8, 2011 RegenoCELL Therapeutics, Inc. (OTCBB: RCLL) , ... announce the opening of another state of the art facility ... failure and peripheral artery disease with its autologous stem cell ... failure is administered at the Metropolitan Hospital in Athens, which ...
... , Amsterdam Molecular Therapeutics (Euronext: AMT), ... today that it has filed,a request for re-examination of ... European Medicines Agency.,Glybera is a gene therapy for the ... re-examination of,the dossier will be completed by the end ...
Cached Biology Technology:Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology 2Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology 3Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology 4Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology 5RegenoCELL Announces That Patients Can Be Treated With Its Autologous Stem Cell Therapy in Greece 2RegenoCELL Announces That Patients Can Be Treated With Its Autologous Stem Cell Therapy in Greece 3Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination 2
(Date:1/22/2015)... the leading source of biometrics industry news, interviews and thought ... "When we launched FindBiometrics 12 years ago the industry ... and CEO of FindBiometrics. "Now it,s maturing very quickly. More ... on a very broad scale.  We are known for providing ...
(Date:1/22/2015)... 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ... on the recent success of the Wocket™ smart wallet at CES 2015 ... wallet was named as one of the "11 Hot Products at CES" ... Launched At CES So Far" by Newseveryday.com and "The top 10 gadgets ...
(Date:1/22/2015)... 2015   EyeLock, Inc. , a market leader of iris-based ... Gerber to the new role of Senior Vice President ... development of mobile platforms and wearable solutions for EyeLock,s technologies. ... in the semiconductor industry to his role at EyeLock, with ...
Breaking Biology News(10 mins):Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2
... for step,ATP splitting in membrane protein dynamically measured for ... of Biological Chemistry How a transport protein ... ATP, has been tracked dynamically by RUB researchers. Using ... the bacterial membrane protein MsbA and its interaction partner ...
... Hormone-mimicking chemicals released into rivers have been found to ... has revealed. The controversial chemical BPA, which emits oestrogen-like ... behavior, leading to inter-species breeding. The study, published in ... when the boundaries between species are blurred. ...
... A new strategy to manage invasive species and ... Grand River Grasslands, an area within the North American ... with his colleagues at Iowa State and Oklahoma State ... to establish a more diverse landscape for native wildlife. ...
Cached Biology News:ATP splitting in membrane protein dynamically measured for the first time 2Hormone-mimicking chemicals cause inter-species mating 2Grassroots approach to conservation developed 2Grassroots approach to conservation developed 3
Porcine parvovirus and mycoplasma tested. Contains 0.5 g/L of trypsin (1:250) and 0.2 g/L of EDTA4Na in Hanks' Balanced Salt Solution without CaCl2 MgCl2 6H2O and MgSO4 7H2O. Contains phenol red....
...
... carry the kanamycin resistance gene that confers ... generation of multiple insertion events can be ... Geneticin Reagent. Pichia transformants are selected on ... of resistance to Geneticin Reagent. The ability ...
Immunogen: Synthetic peptide: R(89) L A F T V D D N P T K P T T R Q R Y(107) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: